
    
      Prednisone, cyclophosphamide, etoposide, and methotrexate regimens are derived from a
      "metronidazole, etoposide, procarbazine and cyclophosphamide (PEPC) regimen" regimen that
      differs from the traditional "maximal Tolerance "chemotherapy, and the use of low-dose
      chemotherapy, frequent drug therapy, the purpose is to anti-angiogenesis and reduce drug
      resistance. At present, the program in our treatment of relapsed or refractory PTCL patients
      effective, safe and controllable, but also look forward to other joint treatment, so as to
      achieve better curative effect. To provide new treatment options for such patients.
    
  